IFW

MAY 1 2 2005 E

Attorney Docket No: 28967/37564B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alitalo et al.

Serial No.: 10/669,176

Filed: September 23, 2003

For: VEGF-C or VEGF-D Materials and Methods for Treatment of

Neuropathologies

) I hereby certify that this paper is being
) deposited with the United States Postal
) Service with sufficient postage as first class

mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

May 10, 2005

Katherine L. Neville

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The patents and/or publications listed on the enclosed PTO Form-1449 are submitted pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the patents or publications are enclosed. The applicants request that the examiner consider the documents and make them of record in the application.

Documents A1-A9, B1-B9, and C1-C62 were submitted in related U.S. Application No. 10/262,538. All other non-U.S. patent documents are submitted herewith.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. In accordance with 37 CFR §1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

The Information Disclosure Statement is submitted before receipt of the first Office Action in the above-mentioned application and as such, no fee is required in connection with filing of this paper.

Please charge any deficiency to Marshall Gerstein and Borun LLP Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

- ENNC

6300 Sears Tower

233 South Wacker Drive

Chicago, Illinois 60606-6357

(312) 474-6300

By:

Katherine L. Neville

Registration No. 53,379

May 10, 2005

Agent for Applicants

U.S. Department of Commerce Patent and Trademark Office Attorney Docket No. 28967/37564B Serial No. 10/669,176

Group

Applicant

Alitalo et al.

Filing Date 09-23-03

1647

INFORMATION DISCLOSURE MAY 1 2 2005 STATEMENT

RADEMARY		U.	S. PATEN	T DOCUMEN	VTS		
Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	5,607,918	03/04/97	Eriksson et al.			
	A2	5,776,755	07/07/98	Alitalo et al.			
	A3	5,840,693	11/24/98	Eriksson et al.			
	A4	6,130,071	10/10/00	Alitalo et al.			
	A5	6,221,839	04/24/01	Alitalo et al.			
	A6	6,235,713	05/22/01	Achen et al.			
	A7	6,245,530	06/12/01	Alitalo et al.			
	A1	5,932,540	08/03/99	Hu et al.	514	2	
	A2	5,935,820	08/10/99	Hu et al.	435	69.4	
	A3	5,952,199	09/14/99	Davis-Smyth	435	69.7	
	A4	6,040,157	03/21/00	Hu et al.	435	69.4	**
	A5	6,100,071	08/08/00	Davis-Smyth	435	69.7	
	A6	6,107,046	08/22/00	Alitalo et al.	435	7.1	
	A7	6,331,302	12/18/01	Bennett	424	146.1	
	A8	6,361,946	03/26/02	Alitalo et al.	435	6	
	A9	6,383,484	05/07/02	Achen et al.	424	133.1	
	A10	6,383,486	05/07/02	Davis-Smyth	424	158.1	
	A11	6,403,088	06/11/02	Alitalo	424	139.1	
	A12	6,451,764	09/17/02	Lee et al.	514	12	
	A13	6,576,608	06/10/03	Lee et al.	514	2	
	A14	6,608,182	08/19/03	Rosen et al.	530	399	
	A15	6,645,933	11/11/03	Alitalo et al.	514	2	
	A16	6,673,343	01/06/04	Bennett et al.	424	133.1	
	A17	6,689,580	02/10/04	Achen et al.	435	69.1	
	A18	6,730,489	05/04/04	Achen et al.	435	7.1	
	A19	6,730,658	05/04/04	Alitalo et al.	514	12	
	A20	2001/0038842	11/08/01	Achen et al.	1.		03-02-200
	A21	2002/0065218	05/30/02	Achen et al.	- -		01-18-200

EXAMINER

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office 09-23-03

INFORMATION DISCLOSURE STATEMENT

				09-2.	5-05	1047
	A22	2002/0102260	08/01/02	Achen et al.		09-20-2001
	A23	2002/0102200	08/29/02	Rosen et al.		04-23-2002
		2002/0120123				<u> </u>
	A24		09/05/02	Oliviero, S.		05-07-2002
	A25	2002/0127222	09/12/02	Achen et al.		12-23-1998
	A26	2002/0146420	10/10/02	Bennett et al.		10-17-2001
	A27	2002/0151489	10/17/02	Gavereaux et al.		10-02-2001
	A28	2002/0182683	12/05/02	Hu et al.		02-01-2002
	A29	2002/0197691	12/26/02	Sugiyama, J.		04-29-2002
	A30	2003/0008357	01/09/03	Hu et al.		08-24-2001
	A31	2003/0028007	02/06/03	Hu et al.		02-28-2002
	A32	2003/0091567	05/15/03	Alitalo et al.		07-23-2002
	A33	2003/0092604	05/15/03	Alitalo et al.		07-23-2002
	A34	2003/0125537	07/03/03	Achen et al.		06-05-2002
,	A35	2003/0166523	09/04/03	Achen et al.		05-03-2001
	A36	2003/0166547	09/04/03	Oliviero, S.		06-19-2002
	A37	2003/0166873	09/04/03	Lee et al.		01-17-2003
	A38	2003/0170786	09/11/03	Rosen et al.		04-12-2002
	A39	2003/0175274	09/18/03	Rosen et al.		04-12-2002
	A40	2003/0176674	09/18/03	Rosen et al.		04-12-2002
	A41	2003/0180294	09/25/03	DeVries, G.		02-22-2002
	A42	2003/0211101	11/13/03	Wise et al.		01-28-2003
	A43	2003/0211988	11/13/03	Epstein, S.		02-14-2003
	A44	2003/0215921	11/20/03	Coleman, T.		08-03-2001
	A45	2003/0228283	12/11/03	Heinzerling et al.		04-29-2003
	A46	2003/0232437	12/18/03	Zhang et al.		06-17-2002
	A47	2004/0037820	02/26/04	Alitalo et al.		01-19-2001
	A48	5,196,315	03/23/93	Ronnett et al.		
	A49	5,654,183	08/05/97	Anderson et al.		
	A50	2002/0045261	4/18/02	Snyder et al.		02/28/01
	A51	2003/0040023	2/27/03	Klassen et al.		04/22/01
		L	L	<u> </u>		L

EXAMINER

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.	Serial No.
28967/37564B	10/669,176
Applicant	

INFORMATION DISCLOSURE STATEMENT

Alitalo et al. Filing Date Group 09-23-03 1647

Examiner Initials		Document	Publication	Country	Class	Subclass	Tr	anslation	
imuais		Number	Date				Yes	No	
	B1	WO 00/21560	04/20/00	PCT				1	
	B2	WO 00/23565	04/27/00	PCT					
	В3	WO 00/25805	05/11/00	PCT					
	B4	WO 01/09157	02/08/01	PCT					
··· · · · · · · · · · · · · · · · · ·	B5	WO 01/31346	05/03/01	PCT	<u> </u>			-	
	B6	WO 96/26736	09/06/96	PCT				1	
	B7	WO 98/07832	02/26/98	PCT	1				
	B8	WO 98/33917	08/06/98	PCT					
	B9	WO 99/29729	06/17/99	PCT			٠.	-	
	B10	EP 0935001	08/11/99	EPO					
	B11	WO 97/12972	04/10/97	PCT				, .	
	B12	WO 98/02543	01/22/98	PCT					
	B13	WO 00/45835	08/10/00	PCT					
	B14	WO 2004/009773	01/29/04	PCT			7	 	
		OTHER DOCUMEN	TS (Including	Author, Title, D	ate, Pertin	ent Pages, e	tc.)		
	C1	Achen et al., "Mono interactions with bo 267:2505-2515, 200	clonal antibooth VEGF rece	lies to vascula	r endothe	lial growt	h factor-D		
	02	Achen, et al., "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (flk1) and VEGF receptor 3 (Flt4)" Proc. Nat'l Acad. Sci. U.S.A., 95(2):548-553, 1998							
	C2	tyrosine kinases VE	GF receptor 2	(flk1) and VE					
	C3	tyrosine kinases VE	GF receptor 2 05(2):548-553 naphorin 3A-vand apoptosis	(flk1) and VE , 1998 rascular endoth of neural prog	EGF receptions and selicities are detected as the selection of the selecti	wth factor	4)" Proc. N	fat'l	
		tyrosine kinases VE Acad. Sci. U.S.A., 9 Bagnard et al., "Sen mediates migration	GF receptor 2 05(2):548-553 naphorin 3A-vand apoptosis Neuroscience 2 ce Lacking the er Hearts, Dys	(flk1) and VE , 1998 rascular endoth of neural prog 21(10):3332-3 Vascular Endosfunctional Co	nelial grogenitor ce 341, 200 lothelial Cronary V	wth factor lls by the state of	4)" Proc. N -165 balan recruitmen ctor-B Ger	ce t of	
	C3	tyrosine kinases VE Acad. Sci. U.S.A., 9 Bagnard et al., "Sen mediates migration shared receptor" J. 1 Bellomo et al., "Mid (Vegfb) Have Small	GF receptor 2 05(2):548-553 naphorin 3A-vand apoptosis Neuroscience 2 ce Lacking the er Hearts, Dys diac Ischemia et al., "Angios	(flk1) and VE , 1998 rascular endoth of neural prog 21(10):3332-3 Vascular Endo functional Co " Circ Res 86: arcomas Expr	nelial grogenitor ce 341, 200 lothelial Cronary V E29-E35	wth factor lls by the selection of the s	4)" Proc. No. 165 balan recruitment ctor-B Ger, and Impa	at'l ce t of ne ired	
	C3	tyrosine kinases VE Acad. Sci. U.S.A., 9 Bagnard et al., "Sen mediates migration shared receptor" J. 1 Bellomo et al., "Mid (Vegfb) Have Small Recovery From Car Breiteneder-Geleff	GF receptor 2 05(2):548-553 naphorin 3A-vand apoptosis Neuroscience 2 ce Lacking the er Hearts, Dys diac Ischemia et al., "Angios ic Capillaries' pilin-2, a Nove or the Semapho	(flk1) and VE, 1998 rascular endoth of neural progential progential progential (flat):3332-3 Vascular Endosfunctional Comparison (flat):3332-3 Vascular Endosfunctional Comparison (flat):332-3 Vascular Endosfunctional Comparison (flat):332-32-32 Vascular Endosfunctional Comparison (flat):332-32-32-32 Vascular Endosfunctional Comparison (flat):332-32-32-32-32-32-32-32-32-32-32-32-32-	nelial grogenitor ce 341, 200 lothelial Gronary V E29-E35 ess Mixed l., 154(2) the Neuro	wth factor lls by the l Growth Fa asculature 5, 2000 d Endothe :385-394, opilin Fam	4)" Proc. No. 165 balan recruitment ctor-B Ger, and Impalial Phenot 1999	ce t of ne ired ypes of	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.	Serial No.
28967/37564B	10/669,176
Applicant	
Alitalo et al.	
Filing Date	Group

09-23-03

INFORMATION DISCLOSURE STATEMENT

		FOI	REIGN PATEN	T DOCUME	ENTS				
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass		Translation	
					<u>. </u>		Yes	No	
	C8	Cohen et al., "Neu Biochem. Biophys	· ·	_	_	Tract Exp	ress Ne	uropilin-2"	
	C9	De Vries et al., "T Growth Factor" So		-	a Recept	tor for Vas	cular E	ndothelial	
	C10	Dumont et al., "Ca Receptor-3" Scien			e Embryo	os Deficier	nt in VE	CGF	
	C11	Ferrara, J., "Molecting J Mol Med 77:527		cal properties	of vascu	lar endoth	elial gr	owth factor"	
	C12	Fujisawa et al., "R biology 8:587-592	-	apsing/semap	horins"	Neuronal	and Gli	al cell	
-	C13		Fujisawa et al., "Roles of a neuronal cell-surface molecule, neuropilin, in nerve fiber fasciculation and guidance" Cell Tissue Res. 290:465-470, 1997						
	C14 Gagnon et al., "Identification of a natural soluble neuropilin-1 that binds endothelial growth factor: <i>In vivo</i> expression and antitumor activity" Proc Sci USA 97(6):2573-2578, 2000								
	C15	Basis of Receptor Function and Specificity" Neuron 21:1079-1092, 1998							
	C16						ce		
	C17 Gluzman-Poltorak et al., "Neuropilin-2 and Neuropilin-1 Are Receptors for Amino Acid Form of Vascular Endothelial Growth Factor (VEGF) and of I Growth Factor-2, but Only Neuropilin-2 Functions as a Receptor for the 14 Acid Form of VEGF*" J. Biol. Chem. 275:(24)18040-18045, 2000				Placenta				
	C18	Hauser et al., "A Heparin-Binding Form of Placenta Growth Factor (PIGF-2) is Expressed in Human Umbilical Vein Endothelial Cells and in Placenta" Growth Factors 9:259-268, 1993							
	C19	He et al., "Neurop Cell 90:739-751.		r for the Axor	nal Chem	orepellent	Semap	horin III"	
	C20	Hirsch et al., "Dist 823:67-79, 1999	ribution of sema	phoring IV ir	adult h	ıman brain	" Brain	Res.	
	C21	Jeltsch et al., "Hyp Science, 276:1423		phatic Vessel	s in VEC	F-C Trans	sgenic N	Mice,"	
	C22	Joukov et al., "A N the Flt4 (VEGFR- 290-298 1996				-	-	_	
·	C23	Joukov et al., "Pro VEGF-C," EMBO			Recepto	r Specifici	ty and A	Activity of	

EXAMINER

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.	Serial No.
28967/37564B	10/669,176
Applicant	· .
Alitalo et al.	
Filing Date	Group

09-23-03

INFORMATION DISCLOSURE STATEMENT

		FOR	EIGN PATEN	I DOCUME	NTS				
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	V	Translation	
 	C24	Joukov et al., "Vasc	ular Endathalia	Crouth Foo	tora FEC	E D and	Yes	No	
	C24	of Cell Physiol 173:	211-215, 1997						
	C25	Jussila et al., "Lymphatic Endothelium and Kaposi's Sarcoma Spindle Cells by Antibodies against in Vascular Endothelial Growth Factor Receptor-3 ¹ " (Res. 58:1599-1604, 1998)							
	C26 Kaipainen et al., "Expression of the FMS-Like Tyrosine Kinase 4 Gene Bec Restricted to Lymphatic Endothelium During Development," <i>Proc. Natl. Act USA</i> , 92:3566-3570 1995								
	C27	Karkkainen et al., "I Nature Cell Biology	· ·		w fronti	er of meta	stasis re	esearch"	
	C28	Karkkainen et al., "I lymphoedema" Nat.			with VE	EGFR-3 si	gnalling	g in primary	
	C29	Kawasaki et al., "A requirement for neuropilin-1 in embryonic vessel formation" Development 126:4895-4902, 1999							
-	C30	Kitsukawa et al., "Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs" Development, 121:4309-4318, 1995							
	C31	Kolodkin et al., "Ne	uropilin Is a Se	maphorin III	Recepto	r" Cell 90	:753-76	2, 1997	
	C32	Maglione et al., "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14" Oncogene 8:925-931, 1993 Makinen et al., "Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expression soluble VEGF receptor-3" <i>Nature Med.</i> 7:(2)199-205 200							
	C33								
	C34								
	C35	Matthews et al., "A enriched primitive h Proc Natl Acad Sci	ematopoietic ce	ells and exhib					
	C36	Meyer et al., "A nov VEGF-E, mediates a VEGFR-1 (Flt-1) re	angiogenesis vi	a signaling th	rough V	EGFR-2 (KDR) t	out not	
	C37	Miao et al., "Neurop progression" FASEI	-	•	ells pror	notes tum	or angio	genesis and	
	C38	Migdal et al., "Neur 273:(35)22272-2227	•	centa Growt	h Factor-	-2 Recepto	or*" J. F	Biol. Chem.	
	C39	Neufeld et al., "Vase J 13:9-22 1999	cular endothelia	l growth fact	or (VEG	F) and its	recepto	ors" <i>FASEB</i>	

EXAMINER

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No. 28967/37564B Applicant Alitalo et al. Filing Date Serial No. 10/669,176 Group

09-23-03

INFORMATION DISCLOSURE STATEMENT

		FO	REIGN PATEN	T DOCUME	ENTS					
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass		Translation		
							Yes	No		
	C40	Olofsson et al., "V endothelial cell" P					wth fact	or for		
	C41	Ortega et al., "Sign	nal Relays in the	VEGF System	n" Fron	Biosci 4:1	41-152,	1999.		
	C42	Pajusola et al., "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors" Oncogene 9:3545-3555, 1994								
	C43	Partanen et al., "V receptor, VEGFR-2096, 2000								
	C44		Pasterkamp et al., "Emerging roles for semaphorins in neural regeneration" Brain Res. Rev. 35:36-54, 2001							
	C45	Growth Factor Re	Pavelock et al., "Differential Expression and Regulation of the Vascular Endothelial Growth Factor Receptors Neuropilin-1 and Neuropilin-2 in Rat Uterus*" Endocrinology 142:613-622, 2001							
	C46	Petrova et al., "Signaling via Vascular Endothelial Growth Factor Receptors" Exp Cell Res 253:117-130, 1999								
	C47	Prevo et al., "Mouse LYVE-1 Is an Endocytic Receotor for Hyaluronan in Lymphatic Endothelium" Biol. Chem. 276:(22) 19420-19430, 2001								
	C48	Robinson et al., "The splice variants of vascular endothelial growth factor (VEGF) and their receptors" J. Cell Science 114:853-865, 2001								
	C49	Rossignol et al., "Human Neuropilin-1 and Neuropilin-2 Map to 10p12 and 2q34, Respectively" Genomics 57:459-460, 1999								
	C50	Rossignol et al., "Genomic Organization of Human Neuropilin-1 and Neuropilin-2 Genes: Identification and Distribution of Splice Variants and Soluble Isoforms" Genomics 70:211-22, 2000								
	C51	Soker et al., "Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor" Cell 92:735-745, 1998								
	C52	Sondell et al., "Va Stimulates Axonal Proliferation in the 19(14):5731-5740	Outgrowth, Enl Peripheral Nerv	nancing Cell S	Survival a	and Schwa	ann Cell	•		
	C53	Sondell et al., "Va stimulates axonal Neuroscience, 12:	outgrowth throug	gh the flk-1 re		_				
	C54	Stacker et al., "The Vascular Develop				Family: S	ignalling	g for		

EXAMINER	DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce Patent and Trademark Office

Serial No. Attorney Docket No. 10/669,176 28967/37564B

IN

NFORM	MATION DISCLOSURE	Applicant Alitalo et al.				
	STATEMENT	Filing Date 09-23-03	Group 1647			
C55	Taipale et al., "Vascular Endothelial G	rowth Factor Recento	x-3" Curr Top Microbiol			
	Immunol 237:85-96 (1999).	io will ractor recopio	13 Curr Top Microbio.			
C56	Takagi et al., "The A5 Antigen, a Candidate for the Neuronal Recognition Molecule, Has Homologies to Complement Components and Coagulation Factors" Neuron 7:295-307, 1991					
C57	Tamagnone et al., "Signalling by semaphoring receptors: cell guidance and beyond" Trends in Cell Biol, 10:377-383, 2000					
C58	Terman et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor" Biochem Biophys Res Comm 187:1579-1586, 1992					
C59	Thompson et al., "PTP-e, a tyrosine ph	osphatase expressed i	n endothelium, negatively			

		7:295-307, 1991
	C57	Tamagnone et al., "Signalling by semaphoring receptors: cell guidance and beyond" Trends in Cell Biol, 10:377-383, 2000
	C58	Terman et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor" Biochem Biophys Res Comm 187:1579-1586, 1992
	C59	Thompson et al., "PTP-e, a tyrosine phosphatase expressed in endothelium, negatively regulates endothelial cell proliferation" Am. J. Phsiol. Heart Circ. Physiol., 281:H396-H403, 2001
	C60	Whitaker et al., "Vascular Endothelial Growth Factor Receptor-2 and Neuropilin-1 Form a Receptor Complex that is Responsible for the Differential Signaling Potency of VEGF ₁₆₅ and VEGF ₁₂₁ *" J. Bio Chem. 276:25520-25531, 2001
	C61	Zachary, "Vascular endothelial growth factor" Intl J Biochem Cell Bio 30:1169-1174 1998
	C62	Bernardi et al., "Respiratory and Cerebrovascular Responses to Hypoxia and Hypercapnia in Familial Dysautonomia", Am. J. Respir. Crit. Care Med. 167: 141-149, 2003
	C63	Bjorklund et al., "Embryonic Stem Cells Develop into Functional Dopaminergic Neurons After Transplantation in a Parkinson Rat Model", <i>Proc. Natl. Acad. Sci</i> 99: 2344-2349, 2002
	C64	Brown et al., "Multiplex Three-Dimensional Brain Gene Expression Mapping in a Mouse Model of Parkinson's Disease", Genome Res. 12: 868-884, 2002
	C65	Crocker et al., "Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in a MPTP Mouse Model of Parkinson's Disease", <i>J. Neurosci</i> 23: 4081-4091, 2003
	C66	Enholm et al., "Adenoviral Expression of Vasular Endothelial Growth Factor-C Induces Lymphangiogensis in the Skin", <i>Circ. Res.</i> 88: 623-629, 2001
	C67	Facchiano et al., "Promotion of Regeneration of Corticospinal Tract Axons in Rats with Recombinant Vascular Endothelial Growth Factor Alone and Combined with Adenovirus Coding for this Factor", <i>J. Neurosurg.</i> 97: 161-168, 2002
	C68	Gage et al., "Survival and Differentiation of Adult Neuronal Progenitor Cells Transplanted to the Adult Brain", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 92: 11879-11883, 1995
	C69	Gage et al., "Isolation, Characterization & Utilization of CNS Stem Cells", Ann Rev Neurosci 18: 159-192, 1995
	C70	Gorio, et al., "Recombinant Human Erythropoietin Counteracts Secondary Injury and Markedly Enhances Neurological Recovery from Experimental Spinal Cord Trauma", <i>Proc. Natl. Acad. Sci.</i> 99: 9450-9455, 2002
EVAMBLED		That covered to

EXAMINER DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce Patent and Trademark Office

	2 ug 0 01 7	
Attorney Docket No.	Serial No.	
28967/37564B	10/669,176	
Applicant		
Alitalo et al.		
Filing Date	Group	
09-23-03	1647	

INFORMATION DISCLOSURE STATEMENT

C71	Hartman et al., "Apolipoprotein E4 Influences Amyloid Deposition but not Cell Loss After Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease", <i>J. Neurosci</i> 22: 10083-10087, 2002
C72	Hickey et al., "Apoptosis in Huntington's Disease", Prog. Neuropsychopharmacol Biol Psychiatry 27: 255-265, 2003
C73	Kaushal et al., "Functional Small-Diameter Neovessels Created Using Endothelial Progenitor Cells Expanded Ex Vivo", Nat. Med. 7:1035-1040, 2001
C74	Kukk et al., "VEGF-C Receptior Binding and Pattern of Expression with VEGFR-3 Suggests a Role in Lymphatic Vascular Development", <i>Development</i> 122: 3829-3837, 1996
C75	Konobu et al., "The hNT Human Neuronal Cell Line Survives and Migrates into Rat Retina", Cell Transplantation 7: 549-558, 1998
C76	Krassioukov et al., "Episodic Hypertension Due to Autonomic Dysreflexia in Acute and Chronic Spinal Cord-Injured Rats", Am J. Physiol. 268: H2077-H2083, 1995
C77	Lacorraza et al., "Expression of Human β-Hexosaminidase α-subunit Gene (the Gene Defect of Tay-Sachs Disease) in Mouse Brains Upon Engraftment of Transduced Progenitor Cells", <i>Nature Med.</i> 4: 424-429, 1996
C78	Laitinen et al., "Adenovirus-Mediated Gene Transfer to Lower Limb Artey of Patients with Chronic Critical Leg Ischemia", <i>Hum. Gene. Ther.</i> 9: 1481-1486, 1998
C79	Lamarre-Cliche et al., "Octreotide for Orthostatic Hypotension", Can J. Clin Pharmacol 6: 213-215, 1999
C80	Mak et al., "The Holmes-Adie Plus Syndrome", J Clin Neurosci 7:452, 2000
C81	McKay, "Stem Cells in the Central Nervous System", Science, 276:66-71, 1997
C82	Nakatomi et al., "Regeneration of Hippocampal Pyramidal Neurons after Ischemic Brain Injury by Recruitment of Endogenous Neural Pregenitors", <i>Cell</i> 110: 429-441, 2002
C83	Oliver et al., "Prox 1, a prospero-related Homebox Gene Exprssed During Mouse Development", Mech. Dev. 44: 3-16, 1993
C84	Patel et al., "Acquired Horner's Syndrome: Clinical Review", Optomery 74: 245-256, 2003
C85	Picard-Riera et al., "Experimetnal Autoimmune Encephalomyelitis Mobilizes Neural Progenitors from the Subventricular Zone to Undergo Oligodendrogenesis in Adult Mice", <i>Proc. Natl. Acad. Sci. USA</i> 99: 13211-13216, 2002
C86	Puumalainen et al., "β-galactosidase Gene Transfer to Human Malignant Glioma In Vivo Using Replication-Deficient Retroviruses and Adenoviruses", Hum. Gene. Ther. 9: 1769-1774, 1998
C87	Quinn et al., "Inflammaton and Cerebral Amyloidosis are Disconnected in an Animal Model of Alzheimer's Disease", <i>J. Neuroimmunol.</i> 137: 32-41, 2003

EXAMINER

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office Attorney Docket No. 28967/37564B 10/669,176

Applicant Alitalo et al.

Filing Date Group

09-23-03

INFORMATION DISCLOSURE STATEMENT

C88	Riess et al., "Transplanted Neural Stem Cells Survive, Differentiate, and Improve Neurological Motor Function After Experimental Traumatuce Brain Injury", Neurosurgery 51: 1043-1054, 2002
C89	Ronnett et al., "Human Cortical Neuronal Cell Line: Establishment from a Patient with Unlateral Megalencephaly", Science 248: 603-605, 1990
C90	Salven et al., "VEGFR-3 and CD133 Identify a Population of CD34+ Lymphatic/Vascular Endothelial Precursor Cells", <i>Blood</i> 101:168-172, 2003
C91	Snyder, "Neural Stem-Like Cells: Developmental Lessons with Therapeutic Potential", <i>The Neuroscientist</i> 4: 408-425, 1998
C92	Snyder et al., "Neural Progenitor Cell Engraftment Corrects Lysosomal Storage Throughout the MPS VII Mouse Brain", <i>Nature</i> 374: 367-370, 1995
C93	Temple, S., "The Development of Neural Stem Cells", Nature 414: 112-117, 2001
C94	Tepper et al., "Endothelial Progenitor Cells: The Promise of Vascular Stem Cells for Plastic Surgery", <i>Plastic and Reconstructive Surgery</i> 111: 846-854, 2003
C95	Turner-Stokes, L., "Reflex Sympathetic Dystrophy – A Complex Regional Pain Syndrome", <i>Disabil Rehabil</i> . 24: 939-947, 2002
C96	Whittemore, et al., "PhysiologicalRelevance and Functional Potential of Central Nervous System-Derived Cell Lines", <i>Mol. Neurobiology</i> 12: 13-38, 1996
C97	Wigle at al., "Prox1 Function is Required for the Development of the Murine Lymphatic System", Cell 98: 769-778, 1999
C98	Wigle et al., "An Essential Role for <i>Prox</i> 1 in the Induction of the Lymphatic Endothelial Cell Phenotype", <i>EMBO J.</i> 21: 1505-1513, 2002

EXAMINER